LGLeila Goudarzimehr

Leila Goudarzimehr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leila Goudarzimehr has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and efficacy of chest tube clamping versus non-clamping prior to removal: a systematic review and meta-analysis

    by Mehdi Kazemloo, Fatemeh Naseri Rad, Leila Goudarzimehr, Mohammadsadra Shamohammadi, Omid Bahrami, Ali Heidari, Matin Emami, Mohammad Baadkoube Hazaveh, Danyal Yarahmadi

    Managing chest tubes before removal remains a controversial clinical issue. Clamping a chest tube before removal is a common practice and is often used to assess latent air leaks. We systematically searched MEDLINE/PubMed, Embase, Scopus, and Web of Science from inception to 11 February 2026 for studies comparing clamping versus no clamping before chest-tube removal. Two reviewers independently screened and extracted data. Random effect meta-analyses used REML with Hartung-Knapp adjustment, pooling risk ratios for pneumothorax and re-intervention, and mean differences (days) for hospital length of stay. The results of this study show no significant differences between the clamping vs. no-clamping in terms of pneumothorax/hemothorax recurrence, re-intervention rates, or hospital length of stay. Within different causes of applying chest tube/ chest drain, routine clamping before chest-tube removal did not reduce early recurrence or the need for re-intervention.

  • Open Access

    Update Prognostic Potency of Vascular Endothelial Growth Factor‐A in the Acute Lymphoblastic Leukemia Landscape: A Meta‐Analysis

    by Mojtaba Aghaei, Mohammad Ali JalaliFar, Arshid Yousefi‐Avarvand, Seyed Sobhan Bahreiny, Negin Karamali, Zahra Mansouri, Mahdi Amraei, Shaban Alizadeh, Najmaldin Saki, Mohammad‐Navid Bastani, et al.

    Background: Vascular endothelial growth factor‐A (VEGF‐A), In combination with other pro‐angiogenic factors, plays a pivotal role in angiogenesis and the pathogenesis of acute lymphoblastic leukemia (ALL).Aims: This meta‐analysis aims to evaluate the diagnostic value of VEGF‐A and its prognostic relevance in the outcome of patients with ALL.Methods and Results: A comprehensive literature search was conducted up to January 2025 across multiple databases. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random‐effects model to quantify effect sizes. Subgroup analyses and meta‐regression were employed to explore heterogeneity sources. Data extracted from 15 studies encompassing 674 patients with ALL demonstrated a significant correlation between elevated VEGF‐A levels and unfavorable prognosis (SMD: 0.878; 95% CI: 0.276–1.479; p = 0.004). Notably, increased VEGF‐A levels were particularly evident in pediatric patients older than 8 years (SMD: 0.758; 95% CI: 0.178–1.338; p = 0.010).Conclusion: The results indicate that heightened VEGF‐A expression is associated with poorer clinical outcomes in ALL, supporting its utility as a diagnostic and prognostic biomarker in this patient population.